Clinical Trials Logo
  1. Home
  2. Anti-Infective Agents
  3. NCT01073540

Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension

Anti-Infective Agents Clinical Trial

Official title:
Prospective, Randomized, Open Label, Crossover Study to Compare the Bioavailability Between Optocef Suspension From Bayer (Cephalexin Suspension 250 mg/5 mL) and Equivalent Concentration of Keflex Pediatrico From Eli Lilly (Cephalexin Suspension 125 mg/5mL) in Healthy Subjects

Clinical Trial Summary

A single dose, two treatments (two cephalexin suspension brands), two sequences, cross-over design was used with a washout of 7 days between the two study periods. Treatment groups balanced with the same number of healthy volunteers who were randomly (in two strata: male and female) assigned to the study drug administration sequences.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01073540
Study type Interventional
Source Bayer
Contact
Status Completed
Phase Phase 1
Start date September 2009
Completion date September 2009
View Details
See also
  Status Clinical Trial Phase
Completed NCT03279120 - Safety, PK, and PD Study of IVRs Releasing TFV and LNG Phase 1
Not yet recruiting NCT03793946 - A Digital Antimicrobial Stewardship Smartphone Application to Combat AMR: the AB-assistant N/A
Completed NCT01073553 - Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Capsules Phase 1
Terminated NCT04489420 - Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM Phase 1
Completed NCT01244698 - Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction Phase 4
Completed NCT01231763 - Acceptability Study of Vaginal Films for HIV Prevention N/A
Active, not recruiting NCT04365101 - Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 Phase 1/Phase 2
Completed NCT01690533 - Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease
Completed NCT01105208 - Cross Over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension Phase 1
Recruiting NCT04310592 - Natural Killer Cell (CYNK-001) Infusions in Adults With AML Phase 1
Completed NCT02046512 - Probiotics to Promote Intestinal Health Phase 4
Completed NCT04210713 - Neuroimmune Dysfunction in Alcohol Use Disorder Phase 1
Completed NCT04448665 - Compliance of Initial Empiric Antimicrobial Therapy
Completed NCT05979207 - Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum Phase 1
Recruiting NCT02242968 - Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products